Key points:
·Focus Event: FDA approval of Juul e-cigarette market entry sparks collective opposition from Democratic senators, demanding explanation of decision-making basis.
·Controversy: FDA's reversal of Juul product sales ban in 2024 is alleged to involve conflicts of interest between the Trump administration and the e-cigarette industry, citing evidence of former Trump advisor's responsibility for Juul federal lobbying.
·Background information: Juul has reached over $1.1 billion in settlements with 48 states and regions for misleading advertising.
·Progress: Senators request FDA to respond to related questions by August 22nd.
【2Firsts News Flash】According to a report by CSP on August 4th, a group of federal lawmakers are opposing the US FDA's decision to issue market access permits (MGOs) for Juul e-cigarettes.
Eight Democratic senators have jointly asked the FDA to explain its decision to approve the Juul e-cigarette, including its mint-flavored electronic pods.
They wrote to FDA Commissioner Marty Makary on July 28, requesting the agency to explain the decision to allow Juul e-cigarettes to continue being sold on the market.
In 2024, the FDA lifted the market denial orders (MDOs) for all products sold by Juul Labs in the United States.
Senators said in a letter:
“We are deeply concerned about the signs of conflicting interests between the Trump administration and the American e-cigarette industry regarding this policy reversal.”
The letter also mentioned:
“For example, former public health and science advisor to President Trump is now responsible for Juul's federal lobbying efforts.”
These federal lawmakers stated that the Washington-based e-cigarette company has reached settlement agreements with 48 states and territories, paying a total amount of over $1.1 billion for its misleading advertising.
Senate Democratic Whip Dick Durbin and other senators are requesting responses to a series of questions by August 22nd, as stated in a letter.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
